New drug combo shows promise for tough lung cancer

NCT ID NCT04736823

Ongoing Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a new drug called AK112, which targets both PD1 and VEGF, combined with standard chemotherapy in 265 people with advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination can shrink tumors and improve outcomes. Participants have stage IIIB/C or IV cancer and are in good enough health to undergo treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK112 (a drug that targets PD1 and VEGF) combined with chemotherapy drugs (pemetrexed, paclitaxel, carboplatin, docetaxel)
What this could lead to: If successful, this could lead to a new treatment option that helps shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer.
What could go wrong: This is a mid-stage trial with no control group, so results are preliminary. The combination may cause side effects like fatigue, low blood counts, or immune-related reactions, and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Sun Yat-Sen University Cancer Center

Guanzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.